Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biote (BTMD) Capital Expenditures (2021 - 2025)

Biote (BTMD) has 5 years of Capital Expenditures data on record, last reported at -$2.9 million in Q3 2025.

  • For Q3 2025, Capital Expenditures fell 37.39% year-over-year to -$2.9 million; the TTM value through Sep 2025 reached $5.9 million, up 99.05%, while the annual FY2024 figure was $6.4 million, 173.15% up from the prior year.
  • Capital Expenditures reached -$2.9 million in Q3 2025 per BTMD's latest filing, down from $3.2 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $5.3 million in Q4 2024 and bottomed at -$2.9 million in Q3 2025.
  • Average Capital Expenditures over 5 years is $649705.9, with a median of $220000.0 recorded in 2022.
  • Peak YoY movement for Capital Expenditures: soared 1265.96% in 2023, then tumbled 227.19% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at -$538000.0 in 2021, then crashed by 60.97% to -$866000.0 in 2022, then surged by 312.01% to $1.8 million in 2023, then soared by 189.43% to $5.3 million in 2024, then crashed by 154.14% to -$2.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were -$2.9 million in Q3 2025, $3.2 million in Q2 2025, and $218000.0 in Q1 2025.